Overexpressed extracellular matrix (ECM) in liver fibrosis limits drug penetration into the tumor and is associated with poor prognosis. Collagen, a triple-helix protein, is the main structural component in such diseases. Collagen viscoelastic properties play a major role in constructing healthy tissues, but pathologic excess production of collagen can contribute to chemoresistance. The new invention utilizes nanoscale liposomal drug delivery system that encapsulates collagenase type-I (collagozome) and releases it in the liver microenvironment. The released enzyme disassembles the collagen component of the liver, and reduced its levels by 35-49%. The collagozome pretreatment increased the liver nanoparticles content.
- Enhancement of tissue permeability before drug administration
Applications and Opportunities
- Degrading the extracellular stroma in fibrotic diseases as well as pancreatic ductal carcinomas